Nabriva On Pace For Lefamulin NDA; Stock Tumbles Despite Trial Success
With a pair of Phase III trials demonstrating lefamulin’s non-inferiority to moxifloxacin in CABP, Nabriva plans to file an NDA later this year. But Nabriva’s share price fell during the day, perhaps due to safety concerns about the first-in-class antibiotic.
You may also be interested in...
Lefamulin was approved in the US to treat community-acquired bacterial pneumonia, providing a needed IV and oral drug initially in the hospital setting, but new antibiotics have been a tough sell.
A roundup of new applications submitted to FDA’s Center for Drug Evaluation and Research.
Axovant was Roivant's star and the first test of its risk-reducing strategy, but the company will attempt to move its spotlight to other assets at an R&D day on July 10. Ahead of the event, Roivant announced a reorganization to strengthen its subsidiaries and accelerate the creation of new ones.